Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2010

Open Access 01-12-2010 | Research

Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis

Authors: David J Graber, William F Hickey, Brent T Harris

Published in: Journal of Neuroinflammation | Issue 1/2010

Login to get access

Abstract

Background

The role of neuroinflammation in motor neuron death of amyotrophic lateral sclerosis (ALS) is unclear. The human mutant superoxide dismutase-1 (hmSOD1)-expressing murine transgenic model of ALS has provided some insight into changes in microglia activity during disease progression. The purpose of this study was to gain further knowledge by characterizing the immunological changes during disease progression in the spinal cord and peripheral nerve using the more recently developed hmSOD1 rat transgenic model of ALS.

Methods

Using immunohistochemistry, the extent and intensity of tissue CD11b expression in spinal cord, lumbar nerve roots, and sciatic nerve were evaluated in hmSOD1 rats that were pre-clinical, at clinical onset, and near disease end-stage. Changes in CD11b expression were compared to the detection of MHC class II and CD68 microglial activation markers in the ventral horn of the spinal cord, as well as to the changes in astrocytic GFAP expression.

Results

Our study reveals an accumulation of microglia/macrophages both in the spinal cord and peripheral nerve prior to clinical onset based on CD11b tissue expression. The microglia formed focal aggregates in the ventral horn and became more widespread as the disease progressed. Hypertrophic astrocytes were not prominent in the ventral horn until after clinical onset, and the enhancement of GFAP did not have a strong correlation to increased CD11b expression. Detection of MHC class II and CD68 expression was found in the ventral horn only after clinical onset. The macrophages in the ventral nerve root and sciatic nerve of hmSOD1 rats were observed encircling axons.

Conclusions

These findings describe for the first time in the hmSOD1 rat transgenic model of ALS that enhancement of microglia/macrophage activity occurs pre-clinically both in the peripheral nerve and in the spinal cord. CD11b expression is shown to be a superior indicator for early immunological changes compared to other microglia activation markers and astrogliosis. Furthermore, we suggest that the early activity of microglia/macrophages is involved in the early phase of motor neuron degeneration and propose that studies involving immunomodulation in hmSOD1transgenic models need to consider effects on macrophages in peripheral nerves as well as to microglia in the spinal cord.
Appendix
Available only for authorised users
Literature
1.
Kawamata T, Akiyama H, Yamada T, McGeer PL: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992, 140: 691-707.PubMedCentralPubMed
2.
Ince PG, Shaw PJ, Slade JY, Jones C, Hudgson P: Familial amyotrophic lateral sclerosis with a mutation in exon 4 of the Cu/Zn superoxide dismutase gene: pathological and immunocytochemical changes. Acta Neuropathol. 1996, 92: 395-403. 10.1007/s004010050535.CrossRefPubMed
3.
Hall ED, Oostveen JA, Gurney ME: Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia. 1998, 23: 249-56. 10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#.CrossRefPubMed
4.
Magnus T, Carmen J, Deleon J, Xue H, Pardo AC, Lepore AC, Mattson MP, Rao MS, Maragakis NJ: Adult glial precursor proliferation in mutant SOD1(G93A) mice. Glia. 2008, 56: 200-8. 10.1002/glia.20604.CrossRefPubMed
5.
Fendrick SE, Xue QS, Streit WJ: Formation of multinucleated giant cells and microglial degeneration in rats expressing a mutant Cu/Zn superoxide dismutase gene. J Neuroinflammation. 2007, 4: 9-10.1186/1742-2094-4-9.PubMedCentralCrossRefPubMed
6.
Alexianu ME, Kozovska M, Appel SH: Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 2001, 57: 1282-9.CrossRefPubMed
7.
Leichsenring A, Linnartz B, Zhu XR, Lubbert H, Stichel CC: Ascending neuropathology in the CNS of a mutant SOD1 mouse model of amyotrophic lateral sclerosis. Brain Res. 2006, 1096: 180-95. 10.1016/j.brainres.2006.04.029.CrossRefPubMed
8.
Weydt P, Moller TCA: Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis. Neuroreport. 2005, 16: 527-31. 10.1097/00001756-200504250-00001.CrossRefPubMed
9.
Papadimitriou D, Le Verche V, Jacquier A, Ikiz B, Przedborski S, Re DB: Inflammation in ALS and SMA: Sorting out the good from the evil. Neurobiol Dis. 2009, Corrected Proof
10.
Kriz J, Nguyen MD, Julien JP: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002, 10: 268-78. 10.1006/nbdi.2002.0487.CrossRefPubMed
11.
Kiaei M, Petri S, Kipiani K, Gardian G, Choi DK, Chen J, Calingasan NY, Schafer P, Muller GW, Stewart C, Hensley K, Beal MF: Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci. 2006, 26: 2467-73. 10.1523/JNEUROSCI.5253-05.2006.CrossRefPubMed
12.
Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF: Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2004, 88: 576-82. 10.1046/j.1471-4159.2003.02160.x.CrossRefPubMed
13.
Werdelin L, Boysen G, Jensen TS, Mogensen P: Immunosuppressive treatment of patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 1990, 82: 132-4. 10.1111/j.1600-0404.1990.tb01602.x.CrossRefPubMed
14.
Appel SH, Stewart SS, Appel V, Harati Y, Mietlowski W, Weiss W, Belendiuk GW: A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol. 1988, 45: 381-6.CrossRefPubMed
15.
Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL, Doorish C, Hilton JF, Spitalny GM, MacArthur RB, Mitsumoto H, Neville HE, Boylan K, Mozaffar T, Belsh JM, Ravits J, Bedlack RS, Graves MC, McCluskey LF, Barohn RJ, Tandan R, Western ALS Study G: Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6: 1045-53. 10.1016/S1474-4422(07)70270-3.CrossRefPubMed
16.
Cudkowicz ME, Shefner JM, Schoenfeld DA, Zhang H, Andreasson KI, Rothstein JD, Drachman DB: Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006, 60: 22-31. 10.1002/ana.20903.CrossRefPubMed
17.
Stommel EW, Cohen JA, Fadul CE, Cogbill CH, Graber DJ, Kingman L, Mackenzie T, Channon Smith JY, Harris BT: Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: A phase II open label clinical trial. Amyotroph Lateral Scler. 2009, 1-12. 10.1080/17482960802709416.
18.
Hensley K, Floyd RA, Gordon B, Mou S, Pye QN, Stewart C, West M, Williamson K: Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Neurochem. 2002, 82: 365-74. 10.1046/j.1471-4159.2002.00968.x.CrossRefPubMed
19.
Hensley K, Fedynyshyn J, Ferrell S, Floyd RA, Gordon B, Grammas P, Hamdheydari L, Mhatre M, Mou S, Pye QN, Stewart C, West M, West S, Williamson KS: Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis. Neurobiol Dis. 2003, 14: 74-80. 10.1016/S0969-9961(03)00087-1.CrossRefPubMed
20.
Xie Y, Weydt P, Howland DS, Kliot M, Moller T: Inflammatory mediators and growth factors in the spinal cord of G93A SOD1 rats. Neuroreport. 2004, 15: 2513-6. 10.1097/00001756-200411150-00016.CrossRefPubMed
21.
Yoshihara T, Ishigaki S, Yamamoto M, Liang Y, Niwa J, Takeuchi H, Doyu M, Sobue G: Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 2002, 80: 158-67. 10.1046/j.0022-3042.2001.00683.x.CrossRefPubMed
22.
Gowing G, Philips T, Van Wijmeersch B, Audet JN, Dewil M, Bosch Van Den L, Billiau AD, Robberecht W, Julien JP: Ablation of Proliferating Microglia Does Not Affect Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis Caused by Mutant Superoxide Dismutase. J Neurosci. 2008, 28: 10234-44. 10.1523/JNEUROSCI.3494-08.2008.CrossRefPubMed
23.
Henkel JS, Beers DR, Siklos L, Appel SH: The chemokine MCP-1 and the dendritic and myeloid cells it attracts are increased in the mSOD1 mouse model of ALS. Mol Cell Neurosci. 2006, 31: 427-37. 10.1016/j.mcn.2005.10.016.CrossRefPubMed
24.
Fischer LR, Culver DG, Tennant P, Davis AA, Wang M, Castellano-Sanchez A, Khan J, Polak MA, Glass JD: Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004, 185: 232-40. 10.1016/j.expneurol.2003.10.004.CrossRefPubMed
25.
Dal Canto MC, Gurney ME: Development of central nervous system pathology in a murine transgenic model of human amyotrophic lateral sclerosis. Am J Clin Pathol. 1994, 145: 1271-9.
26.
Morrison BM, Shu IW, Wilcox AL, Gordon JW, Morrison JH: Early and selective pathology of light chain neurofilament in the spinal cord and sciatic nerve of G86R mutant superoxide dismutase transgenic mice. Exp Neurol. 2000, 165: 207-20. 10.1006/exnr.2000.7457.CrossRefPubMed
27.
Matsumoto A, Okada Y, Nakamichi M, Nakamura M, Toyama Y, Sobue G, Nagai M, Aoki M, Itoyama Y, Okano H: Disease progression of human SOD1 (G93A) transgenic ALS model rats. J Neurosci Res. 2006, 83: 119-33. 10.1002/jnr.20708.CrossRefPubMed
28.
Weydt PCA, Hong SY, Kliot M, Moller T: Assessing disease onset and progression in the SOD1 mouse model of ALS. Neuroreport. 2003, 14: 1051-4. 10.1097/00001756-200305230-00029.PubMed
29.
Cho BP, Sugama S, Shin DH, DeGiorgio LA, Kim SS, Kim YS, Lim SY, Park KC, Volpe BT, Cho S, Joh TH: Microglial phagocytosis of dopamine neurons at early phases of apoptosis. Cell Mol Neurobiol. 2003, 23: 551-60. 10.1023/A:1025024129946.CrossRefPubMed
30.
Bauer J, Sminia T, Wouterlood FG, Dijkstra CD: Phagocytic activity of macrophages and microglial cells during the course of acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neurosci Res. 1994, 38: 365-75. 10.1002/jnr.490380402.CrossRefPubMed
31.
Magnus T, Chan A, Grauer O, Toyka KV, Gold R: Microglial Phagocytosis of Apoptotic Inflammatory T Cells Leads to Down-Regulation of Microglial Immune Activation 1. J Immunol. 2001, 167: 5004-10.CrossRefPubMed
32.
Bo L, Mork S, Kong PA, Nyland H, Pardo CA, Trapp BD: Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol. 1994, 51: 135-46. 10.1016/0165-5728(94)90075-2.CrossRefPubMed
33.
34.
Monaco S, Gehrmann J, Raivich G, Kreutzberg GW: MHC-positive, ramified macrophages in the normal and injured rat peripheral nervous system. J Neurocytol. 1992, 21: 623-34. 10.1007/BF01191724.CrossRefPubMed
35.
Mueller M, Leonhard C, Wacker K, Ringelstein EB, Okabe M, Hickey WF, Kiefer R: Macrophage response to peripheral nerve injury: the quantitative contribution of resident and hematogenous macrophages. Lab Invest. 2003, 83: 175-85.CrossRefPubMed
36.
Mueller M, Wacker K, Ringelstein EB, Hickey WF, Imai Y, Kiefer R: Rapid response of identified resident endoneurial macrophages to nerve injury. Am J Pathol. 2001, 159: 2187-97.PubMedCentralCrossRefPubMed
37.
Keller AF, Gravel M, Kriz J: Live imaging of amyotrophic lateral sclerosis pathogenesis: Disease onset is characterized by marked induction of GFAP in Schwann cells. Glia. 2009, 57: 1130-42. 10.1002/glia.20836.CrossRefPubMed
38.
Ahtoniemi T, Goldsteins G, Keksa-Goldsteine V, Malm T, Kanninen K, Salminen A, Koistinaho J: Pyrrolidine dithiocarbamate inhibits induction of immunoproteasome and decreases survival in a rat model of amyotrophic lateral sclerosis. Mol Pharmacol. 2007, 71: 30-7. 10.1124/mol.106.028415.CrossRefPubMed
39.
Beers DR, Henkel JS, Xiao Q, Zhao W, Wang J, Yen AA, Siklos L, McKercher SR, Appel SH: Wild-type microglia extend survival in PU.1 knockout mice with familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2006, 103: 16021-6. 10.1073/pnas.0607423103.PubMedCentralCrossRefPubMed
40.
Beers DR, Henkel JS, Zhao W, Wang J, Appel SH: CD4 T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA. 2008, 105: 15558-63. 10.1073/pnas.0807419105.PubMedCentralCrossRefPubMed
41.
Chiu IM, Chen A, Zheng Y, Kosaras B, Tsiftsoglou SA, Vartanian TK, Brown RH, Carroll MC: T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc Natl Acad Sci USA. 2008, 105: 17913-8. 10.1073/pnas.0804610105.PubMedCentralCrossRefPubMed
Metadata
Title
Progressive changes in microglia and macrophages in spinal cord and peripheral nerve in the transgenic rat model of amyotrophic lateral sclerosis
Authors
David J Graber
William F Hickey
Brent T Harris
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2010
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-7-8

Other articles of this Issue 1/2010

Journal of Neuroinflammation 1/2010 Go to the issue

Research

Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance

Research

Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models

Research

Spinal motoneuron synaptic plasticity after axotomy in the absence of inducible nitric oxide synthase

Research

Regulation of CCL2 and CCL3 expression in human brain endothelial cells by cytokines and lipopolysaccharide

Research

Herpes simplex virus induces neural oxidative damage via microglial cell Toll-like receptor-2

Research

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease